Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 TrialStefan Dietzsch, Martin Mynarek, Felix Placzek et al.|Advances in Radiation Oncology|2020Cited by 22
Diabetes Mellitus Is a Strong Independent Negative Prognostic Factor in Patients with Brain Metastases Treated with RadiotherapySeong Hoon Jeong, Clemens Seidel, Nils H. Nicolay et al.|Cancers|2023Cited by 2
Short-term survivors with brain metastases have modest benefits from focal and systemic therapies and remain frequent despite improving treatment landscapeM. Czogalla, Clemens Seidel, Jiřı́ Stöhr et al.|Clinical and Translational Radiation Oncology|2025Cited by 2
Hyperglycemia is associated with poor survival in patients with brain metastases treated with radiotherapySoniya Poudyal, Clemens Seidel, Friederike Rothe et al.|Strahlentherapie und Onkologie|2025Cited by 1
MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIALStefan Dietzsch, Martin Mynarek, Felix Placzek et al.|Neuro-Oncology|2020Cited by 0